$CSDX The Low Float Diagnostics Play Eyeing Nasdaq
CS Diagnostics Corp. (OTCQB:CSDX)
Transforming healthcare through innovation and shaping the future of medical technology
Discover the future of healthcare at CS Diagnostics Corp. With our focus on improving therapy outcomes and reducing side effects, we are revolutionizing patient care on a global scale.
Who We Are
CS Diagnostics Corp. a renowned member of the CS Group, is a medical sector leader committed to advancing patient care through innovative solutions. With decades of experience in designing, manufacturing, and selling wellness and medical products, we have established ourselves as a reliable partner in global healthcare.
What We Do
CS Diagnostics Corp. serves a varied international market and specializes in traversing complicated regulatory landscapes to gain product approval and distribution. Our global presence is enhanced by strategic collaborations with healthcare sectors globally, ensuring that our comprehensive services and solutions are available in multiple countries. With a focus on quality and a strong range of solutions, CS Diagnostics Corp. is well-positioned to change the future of healthcare by delivering on our promise of greater health through better technology.
MEDUSA
Introducing the CS-Protect Hydrogel
Experience the future of radiation therapy with our revolutionary hydrogel spacer. Designed to safeguard healthy tissue during prostate cancer treatment, it sets a new standard in precision medicine. As the pinnacle of innovation in prostate cancer care, it maximizes treatment accuracy while minimizing collateral damage, ensuring patients receive cutting-edge care throughout their therapeutic journey.
CS Interpharm and CS Diagnostics Pharma Complete Conversion of Preferred Shares to Common Stock, Strengthening CSDX's Path to Consolidated Financial Reporting
CHEYENNE, WYOMING / ACCESS Newswire / October 31, 2025 / CS Diagnostics Corp. (OTCQB:CSDX), is a Wyoming-incorporated company with principal operations in Cheyenne, Wyoming. The Company designs, manufactures, and distributes advanced medical and wellness products while driving innovation in diagnostics and pharmaceuticals. As part of the CS Group, CSDX and its affiliates serve national and international markets, dedicated to improving patient care and advancing global health, today announced that its key affiliate companies, CS Interpharm and CS Diagnostics Pharma, have successfully completed the conversion of their holdings in the Company's Series B Preferred Stock into unrestricted common stock.
This milestone marks a pivotal advancement in CSDX's strategic roadmap to consolidate financial statements across all affiliated entities by fiscal year-end, December 31, 2025, enabling a more integrated, transparent, and streamlined reporting framework.
Strategic Alignment for Growth and Transparency
Together, CSDX, CS Interpharm, and CS Diagnostics Pharma form a unified group driving innovation in advanced medical, wellness products and life sciences. The Series B Preferred Shares-originally issued to support strategic investments and align affiliate operations-carried dividend preferences and conversion rights.
Following a comprehensive capital structure review, the decision to convert these shares reflects CSDX's commitment to simplification, governance, and long-term value creation. This conversion reduces complexities in financial reporting, eliminates preferred dividend tracking, and establishes a single equity class that better represents the unified organization.
"This share conversion is not merely a technical adjustment but a forward-thinking strategic initiative that underscores our commitment to unity, innovation, and sustainable growth," said Mohammad EsSayed, Principal Financial Officer of CS Diagnostics Corp. "By integrating our affiliates' interests through common shares, we are better equipped to leverage collective expertise in advanced medical, wellness products and life sciences, driving enhanced value for our shareholders as we prepare for fully consolidated financial presentations."
Key Benefits of the Conversion
Enhanced Transparency:
The consolidation will offer investors a complete view of the group's performance, integrating revenue, assets, and operations. Combined financials will reflect product sales, service contracts, and research developments across all entities-providing a holistic picture of CSDX's business strength.
Improved Efficiency:
Aligning share classes streamlines corporate administration, reducing overhead from managing preferred instruments and allowing management to focus on innovation, operational execution, and growth initiatives.
Value Creation for Shareholders:
Affiliates now participate directly in CSDX's growth trajectory as common shareholders, increasing alignment and liquidity while mitigating dilution risks from unconverted preferred shares.
Stronger Capital Market Position:
A unified equity structure enhances CSDX's attractiveness to investors and partners by presenting a cleaner balance sheet, improving access to capital markets, and supporting potential future uplisting or strategic collaborations.
Maintaining Market Integrity and Compliance
To ensure orderly trading conditions, resales of converted shares by affiliates remain subject to Rule 144 of the Securities Act of 1933, including:
- Form 144 Filings: Required for resales exceeding 5,000 shares or $50,000 in aggregate market value within any three-month period.
- Volume Restrictions: Limited to the greater of 1% of the outstanding shares of the same class or the average weekly trading volume over the prior four calendar weeks preceding the filing of the Form 144.
- Public Information: The Company will maintain current public filings to meet disclosure standards.
- Manner of Sale: Resales must be conducted through ordinary brokerage transactions or directly with a market maker, without solicitation of buyers or payment of extraordinary commissions.
These measures underscore CSDX's commitment to ethical practices, investor protection, and long-term shareholder confidence.
Looking Ahead
With consolidated financial reporting on the horizon, CSDX anticipates significant operational synergies across its group-ranging from shared R&D pipelines and supply chain optimization to enhanced product development collaboration. The integration of affiliate revenues and profits will reinforce CSDX's growth, profitability, and competitive position in global medical and life sciences markets.
CS Group (OTCQB: CSDX) Secures Strategic Manufacturing Partnerships, Accelerating Global Commercial Launch of MEDUSA SDP Hygiene Products
CS Diagnostics Corp. (OTCQB: CSDX), a medical technology and hygiene solutions company, today announced the confirmation of strategic manufacturing partnerships with Emirate Wet Wipes LLC that accelerate the Company’s transition into full commercial production ahead of the global launch of MEDUSA SDP, its next-generation medical-grade wet wipes and liquid disinfectant hygiene products designed for healthcare, institutional, and consumer markets.
Under the agreements, Emirate Wet Wipes LLC has been contracted to manufacture the MEDUSA SDP disinfectant wet wipes product line, while Gulf Centre Group Factory will produce bulk liquid hygiene and disinfectant formulations, including 500ml bottles and 5-liter commercial formats. These partnerships provide scalable manufacturing capacity, quality-controlled production, and compliance with regional and international health, safety, and medical manufacturing standards, supporting distribution across hospitals, clinics, retail chains, and e-commerce platforms.
Management stated that securing dedicated manufacturing partners represents a major commercialization milestone, moving MEDUSA SDP from development into revenue-ready production. The partnerships position CS Diagnostics to meet near-term global demand, support international distribution, and maintain operational flexibility as the Company expands across infection control, hospital hygiene, disinfectant products, and medical sanitation markets.
The Company noted that MEDUSA SDP is designed to address rising demand for infection prevention solutions, hospital-acquired infection reduction, and everyday hygiene products, aligning with long-term healthcare spending trends and increased regulatory focus on sanitation, public health, and environmental safety.
“Securing these strategic manufacturing partnerships is a pivotal step in advancing MEDUSA SDP from development into full-scale commercial production,” said Mohammad Essayed, Chief Financial Officer of CS Diagnostics Corp. “By aligning with experienced, quality-driven manufacturers, we are establishing the operational foundation needed to meet rising global demand for infection prevention and hygiene solutions. These agreements accelerate our timeline toward international launch and position CS Diagnostics to deliver scalable, compliant, and medically trusted products across healthcare, institutional, and consumer markets worldwide.”
No comments